2,514 results on '"Soria, Jean-Charles"'
Search Results
2. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
3. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
4. Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience
5. Twitter as a Medical Media Among French Young Oncologists: Results from a National Survey
6. The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape
7. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
8. Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data
9. High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
10. Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials
11. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
12. Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome
13. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
14. Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers
15. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis
16. Targeting the DNA damage response in immuno-oncology: developments and opportunities
17. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
18. Late phase 1 studies: concepts and outcomes
19. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
20. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer
21. Patterns of progression in patients treated for immuno-oncology antibodies combination
22. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer
23. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort
24. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival
25. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
26. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology
27. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
28. Caring for patients with cancer in the COVID-19 era
29. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
30. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
31. Immune Therapies in Phase 1 Trials
32. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer
33. BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer
34. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
35. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
36. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
37. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
38. Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience
39. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers
40. Does smoking alter the mutation profile of human papillomavirus–driven head and neck cancers?
41. Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors
42. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door
43. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
44. Are phase I trials safe for older patients?
45. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
46. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
47. Genomic characterization of metastatic breast cancers
48. Optimizing oncolytic virotherapy in cancer treatment
49. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma
50. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.